People with mild-to-moderate cystic fibrosis (CF) commonly experience a decline in lung function and an uptick in exacerbations shortly after…
Articles by Marisa Wexler, MS
The Cystic Fibrosis Foundation has invested $1 million in Felix Biotechnology to support the company’s efforts to develop a…
For people with cystic fibrosis (CF) who are not eligible for treatment with a CFTR modulator, seeing other…
Yale University last month launched the Center for Phage Biology and Therapy, a new endeavor to advance research into using…
An international team led by scientists at the University of Toronto identified hundreds of proteins, from among nearly…
A team of scientists in New York has created small molecules called antisense oligonucleotides that could be used to “skip…
People with cystic fibrosis (CF) can have a complicated relationship with food and eating that changes over their lifetime,…
First Wave BioPharma has filed two new patents related to adrulipase, a yeast-derived enzyme that the company is developing…
The Cystic Fibrosis Foundation has awarded up to $3.5 million to Aceragen to support the clinical development of…
The European Commission has expanded its approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat children with cystic…